Phase III clinical trial development

A process of chutes and ladders

David Dilts, Steven K. Cheng, Joshua S. Crites, Alan B. Sandler, James H. Doroshow

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Purpose: The Institute of Medicine report on cooperative groups and the National Cancer Institute (NCI) report from the Operational Efficiency Working Group both recommend changes to the processes for opening a clinical trial. This article provides evidence for the need for such changes by completing the first comprehensive review of all the time and steps required to open a phase III oncology clinical trial and discusses the effect of time to protocol activation on subject accrual. Methods: The Dilts and Sandler method was used at four cancer centers, two cooperative groups, and the NCI Cancer Therapy Evaluation Program. Accrual data were also collected. Results: Opening a phase III cooperative group therapeutic trial requires 769 steps, 36 approvals, and a median of approximately 2.5 years from formal concept review to study opening. Time to activation at one group ranged from 435 to 1,604 days, and time to open at one cancer center ranged from 21 to 836 days. At centers, group trials are significantly more likely to have zero accruals (38.8%) than non-group trials (20.6%; P <0.0001). Of the closed NCI Cancer Therapy Evaluation Program-approved phase III clinical trials from 2000 to 2007, 39.1% resulted in

Original languageEnglish (US)
Pages (from-to)5381-5389
Number of pages9
JournalClinical Cancer Research
Volume16
Issue number22
DOIs
StatePublished - Nov 15 2010

Fingerprint

Phase III Clinical Trials
National Cancer Institute (U.S.)
Program Evaluation
Neoplasms
National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division
Therapeutics
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dilts, D., Cheng, S. K., Crites, J. S., Sandler, A. B., & Doroshow, J. H. (2010). Phase III clinical trial development: A process of chutes and ladders. Clinical Cancer Research, 16(22), 5381-5389. https://doi.org/10.1158/1078-0432.CCR-10-1273

Phase III clinical trial development : A process of chutes and ladders. / Dilts, David; Cheng, Steven K.; Crites, Joshua S.; Sandler, Alan B.; Doroshow, James H.

In: Clinical Cancer Research, Vol. 16, No. 22, 15.11.2010, p. 5381-5389.

Research output: Contribution to journalArticle

Dilts, D, Cheng, SK, Crites, JS, Sandler, AB & Doroshow, JH 2010, 'Phase III clinical trial development: A process of chutes and ladders', Clinical Cancer Research, vol. 16, no. 22, pp. 5381-5389. https://doi.org/10.1158/1078-0432.CCR-10-1273
Dilts, David ; Cheng, Steven K. ; Crites, Joshua S. ; Sandler, Alan B. ; Doroshow, James H. / Phase III clinical trial development : A process of chutes and ladders. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 22. pp. 5381-5389.
@article{89f75df662e6471e81fd26152992d6a1,
title = "Phase III clinical trial development: A process of chutes and ladders",
abstract = "Purpose: The Institute of Medicine report on cooperative groups and the National Cancer Institute (NCI) report from the Operational Efficiency Working Group both recommend changes to the processes for opening a clinical trial. This article provides evidence for the need for such changes by completing the first comprehensive review of all the time and steps required to open a phase III oncology clinical trial and discusses the effect of time to protocol activation on subject accrual. Methods: The Dilts and Sandler method was used at four cancer centers, two cooperative groups, and the NCI Cancer Therapy Evaluation Program. Accrual data were also collected. Results: Opening a phase III cooperative group therapeutic trial requires 769 steps, 36 approvals, and a median of approximately 2.5 years from formal concept review to study opening. Time to activation at one group ranged from 435 to 1,604 days, and time to open at one cancer center ranged from 21 to 836 days. At centers, group trials are significantly more likely to have zero accruals (38.8{\%}) than non-group trials (20.6{\%}; P <0.0001). Of the closed NCI Cancer Therapy Evaluation Program-approved phase III clinical trials from 2000 to 2007, 39.1{\%} resulted in",
author = "David Dilts and Cheng, {Steven K.} and Crites, {Joshua S.} and Sandler, {Alan B.} and Doroshow, {James H.}",
year = "2010",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-10-1273",
language = "English (US)",
volume = "16",
pages = "5381--5389",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Phase III clinical trial development

T2 - A process of chutes and ladders

AU - Dilts, David

AU - Cheng, Steven K.

AU - Crites, Joshua S.

AU - Sandler, Alan B.

AU - Doroshow, James H.

PY - 2010/11/15

Y1 - 2010/11/15

N2 - Purpose: The Institute of Medicine report on cooperative groups and the National Cancer Institute (NCI) report from the Operational Efficiency Working Group both recommend changes to the processes for opening a clinical trial. This article provides evidence for the need for such changes by completing the first comprehensive review of all the time and steps required to open a phase III oncology clinical trial and discusses the effect of time to protocol activation on subject accrual. Methods: The Dilts and Sandler method was used at four cancer centers, two cooperative groups, and the NCI Cancer Therapy Evaluation Program. Accrual data were also collected. Results: Opening a phase III cooperative group therapeutic trial requires 769 steps, 36 approvals, and a median of approximately 2.5 years from formal concept review to study opening. Time to activation at one group ranged from 435 to 1,604 days, and time to open at one cancer center ranged from 21 to 836 days. At centers, group trials are significantly more likely to have zero accruals (38.8%) than non-group trials (20.6%; P <0.0001). Of the closed NCI Cancer Therapy Evaluation Program-approved phase III clinical trials from 2000 to 2007, 39.1% resulted in

AB - Purpose: The Institute of Medicine report on cooperative groups and the National Cancer Institute (NCI) report from the Operational Efficiency Working Group both recommend changes to the processes for opening a clinical trial. This article provides evidence for the need for such changes by completing the first comprehensive review of all the time and steps required to open a phase III oncology clinical trial and discusses the effect of time to protocol activation on subject accrual. Methods: The Dilts and Sandler method was used at four cancer centers, two cooperative groups, and the NCI Cancer Therapy Evaluation Program. Accrual data were also collected. Results: Opening a phase III cooperative group therapeutic trial requires 769 steps, 36 approvals, and a median of approximately 2.5 years from formal concept review to study opening. Time to activation at one group ranged from 435 to 1,604 days, and time to open at one cancer center ranged from 21 to 836 days. At centers, group trials are significantly more likely to have zero accruals (38.8%) than non-group trials (20.6%; P <0.0001). Of the closed NCI Cancer Therapy Evaluation Program-approved phase III clinical trials from 2000 to 2007, 39.1% resulted in

UR - http://www.scopus.com/inward/record.url?scp=78349257470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349257470&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-1273

DO - 10.1158/1078-0432.CCR-10-1273

M3 - Article

VL - 16

SP - 5381

EP - 5389

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -